Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$28.26

52W Range

$22.24 - $46.00

50D Avg

$28.10

200D Avg

$34.05

Market Cap

$1.64B

Avg Vol (3M)

$1.10M

Beta

0.88

Div Yield

-

AGIO Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

486

IPO Date

Jul 24, 2013

Website

AGIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 23
Product	$54.03M	$36.50M	$26.82M
Royalty	-	-	-

Fiscal year ends in Dec 25 | Currency in USD

AGIO Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$54.03M	$36.50M	$26.82M
Operating Income	$-472.13M	$-425.74M	$-391.49M
Net Income	$-412.78M	$673.73M	$-352.09M
EBITDA	$-472.13M	$-420.08M	$-384.86M
Basic EPS	$-7.12	$11.86	$-6.33
Diluted EPS	$-7.12	$11.64	$-6.33

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 12, 26 | 8:00 AM

Q3 25Oct 30, 25 | 8:00 AM

Q2 25Jul 31, 25 | 8:00 AM

Peer Comparison

Ticker	Company
GLPG	Galapagos N.V.
SRPT	Sarepta Therapeutics, Inc.
RCUS	Arcus Biosciences, Inc.
RXRX	Recursion Pharmaceuticals, Inc.
DNLI	Denali Therapeutics Inc.
BEAM	Beam Therapeutics Inc.
IBRX	ImmunityBio, Inc.
COGT	Cogent Biosciences, Inc.
LQDA	Liquidia Corporation